Owlstone Medical Ltd, Cambridge, UK, has been spun out of parent company Owlstone Inc to develop and commercialize a breathalyzer for use in clinical diagnostics and precision medicine, with applications in cancer, and inflammatory and infectious disease.
Read MoreAn international group of lung cancer experts has announced the public comment period for a revised guideline on molecular testing to improve patient selection and targeted therapies.
Read MoreEarly FDA approvals hint that the floodgates for so-called “liquid biopsy” technologies are about to be thrown wide open.
Read More
The recent FDA premarket approval for the Epi ProColon colorectal cancer screening test by Epigenomics AG highlights the potential of liquid biopsy methods.
Read MoreMany tests have been shown both to find cancer early and to lower the chance of dying from the disease.
Read More